MEASuRE: Metreleptin Effectiveness And Safety Registry

The MEASuRE study, which stands for Metreleptin Effectiveness And Safety Registry, is designed to gather important long-term information about a medicine called metreleptin. This medicine is used to treat rare conditions called lipodystrophy, where the body either loses fat tissue generally (Generalised Lipodystrophy) or in specific areas (Partial Lipodystrophy). This isn't a new drug trial; instead, it's a careful way of observing how the medicine works for people who are already receiving it as part of their usual medical care.

The main goal of this study is to collect information from a large number of patients over time. This helps doctors and researchers understand the medicine better than they could from shorter, controlled trials. They are particularly interested in looking at specific side effects that might not show up often in smaller studies, such as issues with the pancreas (like pancreatitis), liver problems, low blood sugar (hypoglycemia), serious infections, allergic reactions, and even how the medicine might affect existing or new autoimmune conditions, or if it loses its effectiveness over time.

By collecting data from people using metreleptin in their daily lives, the study aims to provide a more complete picture of its safety and how well it works. This knowledge is incredibly valuable for healthcare professionals and patients alike, as it helps everybody make more informed decisions about the use of metreleptin for lipodystrophy.